Compounds for use in polycystic kidney disease
AssigneesFondazione Centro San Raffaele Office of Biotechnology Transfer, Fondazione Telethon
InventorsAlessandra Boletta, Marco Chiaravalli, Isaline Severine Marie-Josephe Rowe
Life of this patent
Estimating the term…
Abstract
Polycystic kidney disease is a cystic genetic disorder of the kidneys. Recent identification of signaling cascades de-regulated in PKD has led to the initiation of several clinical trials, but an effective therapy is still lacking. A new therapeutic paradigm is capable of improving the proliferation rate and cystic kidney volume in PKD.
Claims11
A method of treating autosomal dominant polycystic kidney disease (ADPKD) in a subject in need thereof, comprising administering an effective amount of a pharmaceutical composition comprising 2-deoxyglucose (2DG).
Dependencies are inferred from the claim text.